Predicting Neutropenia in Chemotherapy Patients
Author Information
Author(s): LÓPEZ-POUSA A, RIFÀ J, CASSAS DE TEJERINA A, GONZÁLEZ-LARRIBA JL, IGLESIAS C, GASQUET JA, CARRATO A
Primary Institution: Santa Creu i Sant Pau Hospital
Hypothesis
The study aims to develop a model to predict first-cycle chemotherapy-induced neutropenia in patients with solid tumours.
Conclusion
The risk assessment model can identify high- and low-risk patients for chemotherapy-induced neutropenia before treatment begins.
Supporting Evidence
- The incidence of grades 3–4 neutropenia was 10% during the first cycle of chemotherapy.
- The model's sensitivity and specificity were 63% and 67%, respectively.
- Patients with an ECOG status of 2 had a higher risk of neutropenia compared to those with an ECOG of 0.
- Baseline lymphocyte and neutrophil counts were inversely related to the risk of neutropenia.
Takeaway
Doctors can use this model to figure out which patients are more likely to get sick from chemotherapy, helping them take better care of those patients.
Methodology
A multi-centre, prospective, non-interventional cohort study was conducted to assess the risk of neutropenia during the first three chemotherapy cycles.
Potential Biases
Potential biases may arise from the non-interventional design and the diversity of chemotherapy regimens.
Limitations
The model needs validation in different populations and may not fit all patient characteristics and chemotherapy regimens.
Participant Demographics
56% women, mean age 58 ± 12 years, 94% with ECOG status ≤1.
Statistical Information
P-Value
0.003
Confidence Interval
95% confidence interval for odds ratios provided in the results.
Statistical Significance
p<0.0005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website